Table 1. Characteristics of the included studies.
| Study (year) | Patients with HCC/controls | GP73 | GPC-3 | AFP | GPC-3 + AFP | GP73 + AFP | GP73 + GPC-3 + AFP | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TP | FP | FN | TN | Method | TP | FP | FN | TN | Method | TP | FP | FN | TN | Method | TP | FP | FN | TN | TP | FP | FN | TN | TP | FP | FN | TN | |||||||
| Yang Hua-Yu (2013) | 45/72 | 36 | 1 | 9 | 71 | WB | 14 | 6 | 31 | 66 | EL | 26 | 7 | 19 | 65 | IA | 33 | 12 | 12 | 60 | 42 | 8 | 3 | 64 | 43 | 13 | 2 | 59 | |||||
| Zhang Hua (2014) | 60/106 | 41 | 10 | 19 | 96 | EL | 38 | 4 | 22 | 102 | EL | 32 | 8 | 28 | 98 | IA | 44 | 8 | 16 | 98 | 48 | 17 | 12 | 89 | 52 | 18 | 8 | 18 | |||||
| Huo Yi-Shan (2017) | 90/120 | 63 | 30 | 28 | 76 | EL | 65 | 15 | 26 | 91 | EL | 59 | 26 | 32 | 80 | IA | – | – | – | – | – | – | – | – | 74 | 6 | 17 | 100 | |||||
| Lv Song-Lin (2019) | 34/58 | 18 | 6 | 16 | 52 | WB | 19 | 6 | 15 | 52 | EL | 15 | 8 | 19 | 50 | IA | – | – | – | – | – | – | – | – | 33 | 7 | 1 | 51 | |||||
| Hao Rui (2018) | 65/222 | 51 | 55 | 14 | 167 | EL | 39 | 44 | 26 | 178 | EL | 37 | 37 | 28 | 185 | IA | 45 | 54 | 20 | 168 | 59 | 71 | 6 | 151 | 62 | 85 | 3 | 137 | |||||
| Zhao Tian-Tian (2017) | 90/120 | 83 | 6 | 7 | 114 | EL | 79 | 4 | 11 | 116 | EL | 82 | 9 | 8 | 111 | IA | – | – | – | – | – | – | – | – | 82 | 18 | 8 | 110 | |||||
| Zhu Bo (2016) | 194/224 | 152 | 3 | 42 | 221 | EL | 103 | 11 | 91 | 213 | EL | 114 | 18 | 80 | 206 | IA | – | – | – | – | – | – | – | – | 184 | 28 | 10 | 196 | |||||
| Fan Gong-Ren (2014) | 148/215 | – | – | – | – | EL | – | – | – | – | EL | 113 | 35 | 35 | 180 | IA | 116 | 31 | 32 | 184 | 118 | 34 | 30 | 181 | 142 | 40 | 6 | 175 | |||||
| Long Lu (2013) | 43/132 | 37 | 8 | 6 | 124 | EL | 23 | 7 | 20 | 125 | EL | 33 | 18 | 10 | 111 | IA | 38 | 25 | 5 | 107 | 42 | 25 | 1 | 107 | 42 | 31 | 1 | 98 | |||||
| Zhao Yun-Sheng (2012) | 50/80 | 36 | 4 | 14 | 76 | EL | 21 | 3 | 29 | 77 | EL | – | – | – | – | IA | – | – | – | – | 44 | 10 | 6 | 70 | 44 | 12 | 6 | 68 | |||||
| Li Hui (2016) | 50/100 | 36 | 6 | 14 | 94 | EL | – | – | – | – | EL | – | – | – | – | IA | – | – | – | – | 36 | 6 | 14 | 94 | 38 | 7 | 12 | 93 | |||||
| Zhao Yun-Sheng (2017) | 50/100 | 36 | 6 | 14 | 94 | EL | – | – | – | – | EL | 26 | 6 | 24 | 74 | IA | 26 | 2 | 24 | 98 | 36 | 6 | 14 | 94 | 39 | 7 | 11 | 93 | |||||
HCC, hepatocellular carcinoma; TP, true positive; FP, false positive; FN, false negative; TN, true negative; EL, ELISA; WB, Western blot; IA, immunoassay.